Polymorphism at position -308 of the tumour necrosis factor alpha gene and rheumatoid arthritis pharmacogenetics.
about
Genome-wide association scan identifies candidate polymorphisms associated with differential response to anti-TNF treatment in rheumatoid arthritisContribution for new genetic markers of rheumatoid arthritis activity and severity: sequencing of the tumor necrosis factor-alpha gene promoterTNF-α Polymorphisms in Juvenile Idiopathic Arthritis: Which Potential Clinical Implications?Protein therapeutics: new applications for pharmacogenetics.A single tumour necrosis factor haplotype influences the response to adalimumab in rheumatoid arthritis.Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritis.Psoriatic arthritis: genetic susceptibility and pharmacogenetics.Gene polymorphisms and pharmacogenetics in rheumatoid arthritisA genetic risk score composed of rheumatoid arthritis risk alleles, HLA-DRB1 haplotypes, and response to TNFi therapy - results from a Swedish cohort study.The latest advances in pharmacogenetics and pharmacogenomics in the treatment of psoriasis.Genetic and genomic predictors of anti-TNF response.Pharmacogenetics of disease-modifying antirheumatic drugs in rheumatoid arthritis: towards personalized medicine.Pharmacogenomics of biological treatment in rheumatoid arthritis.Clinical parameters and biomarkers for anti-TNF treatment prognosis in rheumatoid arthritis patients.The effect of gene polymorphisms on patient responses to rheumatoid arthritis therapy.Selected cytokine pathways in rheumatoid arthritis.Association of tumour necrosis factor-alpha -308 G/A promoter polymorphism with susceptibility and disease profile of rheumatoid arthritis.Understanding Personalized Medicine in Rheumatoid Arthritis: A Clinician's Guide to the Future.Pharmacogenetics of anti-TNF treatment in patients with rheumatoid arthritis.TRAF1/C5 but not PTPRC variants are potential predictors of rheumatoid arthritis response to anti-tumor necrosis factor therapy.
P2860
Q24647387-79723652-1323-4EFA-B288-A22A6EA5C99DQ35869031-1751179D-A965-445E-9A82-7EC600D52F69Q36361083-A7BBEA18-7CAB-49D9-8B6A-1243E2314BC0Q36501235-3E5B0AD3-1A8A-403B-8AC1-A09E516DAA49Q36900659-C6CEE4F5-D0F4-4EE6-ABED-74152C061DD5Q37000109-607EBA44-18CE-415C-9354-E15768B0D913Q37120837-32740C2D-A8CE-4C26-9927-A85D6D177E01Q37214931-E552013F-8CD2-4772-B59B-F60F613FB175Q37470261-A7E5086C-8F5B-4248-A509-CFF8F9688D0DQ37722744-FDB0AE2D-8BDD-481C-999E-FEF49B0164C7Q37951648-83F0C8CE-BAC5-4A83-9EA8-5C2A1AA4A808Q38084444-D25F160B-A2A5-4BBD-AF13-BCADC633FCABQ38167894-D9DDAC11-D729-4C80-9299-A99D8DEBD915Q38236144-D4771899-049E-4081-BED1-A4F0F72914B1Q38648460-AAEF937B-7CA8-4C5B-BE08-846C67A00CA4Q38755912-837A3AE3-7C73-400B-8295-42B59446707DQ39272864-5D1EA9B1-E840-48A5-93F0-655DBFF49A72Q39991278-82643CAE-21D1-41A9-8D93-4EE77CF5A8E3Q40191979-0B43F2CA-145B-42D4-AC20-F7B15E1B73F6Q41830089-F2F9FE7B-2981-4C67-870B-8081713689FB
P2860
Polymorphism at position -308 of the tumour necrosis factor alpha gene and rheumatoid arthritis pharmacogenetics.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Polymorphism at position -308 ...... id arthritis pharmacogenetics.
@en
Polymorphism at position -308 ...... id arthritis pharmacogenetics.
@nl
type
label
Polymorphism at position -308 ...... id arthritis pharmacogenetics.
@en
Polymorphism at position -308 ...... id arthritis pharmacogenetics.
@nl
prefLabel
Polymorphism at position -308 ...... id arthritis pharmacogenetics.
@en
Polymorphism at position -308 ...... id arthritis pharmacogenetics.
@nl
P2093
P50
P356
P1476
Polymorphism at position -308 ...... oid arthritis pharmacogenetics
@en
P2093
P304
P356
10.1136/ARD.2004.028167
P407
P577
2005-05-01T00:00:00Z